At the news
? BEARISHIMPACT 5/10 PRESS-RELEASE filed Nov 5, 2026 at 16:34 ET
Nkarta reported Q3 2026 net loss of $33.3M ($0.45 per share), wider than the $0.38 consensus estimate and the year-ago $0.29 loss. Cash burn continues with $216M remaining, funding operations into 2029. Initial clinical data for NKX019 in myositis and systemic sclerosis will be presented at ACR Convergence 2026, a key catalyst.
- Net loss of $33.3M ($0.45 per share) for Q3 2026, wider than consensus estimate of $0.38 loss
- Revenue was $0, consistent with pre-revenue clinical-stage biotech
- Cash, cash equivalents, restricted cash, and investments totaled $216.0M as of September 30, 2026, down from $295.1M at year-end 2025
- R&D expenses rose to $29.5M from $20.2M in Q3 2025, a 46% increase
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access